Variant · Snv

TP53 H179R

CI-VAR-00001907Explore in graph →NP_000537.3:p.His179ArgNM_000546.5:c.536A>GClinVar 376606 CIViC 1082 rs1057519991

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Unmapped disease2unmapped disease
TP53 H179R	(functional)	Functional	D	Supports Loss Of Function	2	submitted	EID9444 Fifty missense mutations identified in sporadic breast cancer were assessed for qualitative and quantitative changes in their ability to transactivate from 11 human promoter response elements in a yea… (full text at CIViC) PMID 20407015 · Jordan et al., 2010 · Open in CIViC	civic
TP53 H179R	(functional)	Functional	D	Supports Dominant Negative	3	accepted	EID10530 Yeast strain yIG397 was cultured to express both wild-type (WT) and mutant H179R originally identified in an oral lesion. Should the mutant be dominant-negative (DN), TP53 will not bind and transactiv… (full text at CIViC) PMID 10519380 · Marutani et al., 1999 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
376606	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts	2	Li-Fraumeni syndrome; Ovarian neoplasm; Hereditary cancer-predisposing syndrome; TP53-related disorder; Li-Fraumeni syndrome 1; Uterine corpus endometrial carcinoma; Gastric cancer; Squamous cell lung carcinoma; Ovarian serous cystadenocarcinoma; Uterine carcinosarcoma; Pancreatic adenocarcinoma; Squamous cell carcinoma of the head and neck; Malignant tumor of urinary bladder; Colon adenocarcinoma; Glioma susceptibility 1; Acute myeloid leukemia; Familial cancer of breast; Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype; Medulloblastoma SHH activated and TP53 mutant; Astrocytoma IDH-mutant; Neoplasm